Home Newsfeeds Lazard: Q2 Earnings Insights

Lazard: Q2 Earnings Insights

Lazard (NYSE:LAZ) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:49 AM. Here's what investors need to know about the announcement. Earnings Lazard beat estimated earnings by 6.98%, reporting an EPS of $0.92 versus an estimate of $0.86.

byBenzinga Insights

July 28, 2022

1 minute read

Lazard (NYSE:LAZ) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:49 AM.

Here’s what investors need to know about the announcement.

Earnings

Lazard beat estimated earnings by 6.98%, reporting an EPS of $0.92 versus an estimate of $0.86.

Revenue was down $145.53 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.18 which was followed by a 4.04% drop in the share price the next day.

Here’s a look at Lazard’s past performance:

Quarter	Q1 2022	Q4 2021	Q3 2021	Q2 2021
EPS Estimate	0.87	1.44	0.95	0.88
EPS Actual	1.05	1.92	0.98	1.28
Revenue Estimate	673.91M	858.32M	715.32M	652.31M
Revenue Actual	698.63M	967.95M	701.64M	821.45M

To track all earnings releases for Lazard visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Keybanc Maintains Overweight on Lululemon Athletica, Raises Price Target to $375

By Benzinga Newsdesk

September 2, 4:31 AM

Keybanc analyst Noah Zatzkin maintains Lululemon Athletica (NASDAQ:LULU) with a Overweight and raises the price target from $350 to $375.

LULU

Huntington Ingalls Industries See FY24 Free Cash Flow Of $600-$700M

By Benzinga Newsdesk

February 1, 8:18 AM

FY24 Outlook1 Shipbuilding Revenue2 $8.8B - $9.1B Shipbuilding Operating Margin2 7.6% - 7.8% Mission Technologies Revenue $2.7B - $2.75B Mission Technologies Segment

HII

Hempacco Stock Plummets On Upsized $6.3M Public Offering

By Vuk Zdinjak

February 10, 10:56 AM

Hempacco Co., Inc. (NASDAQ: HPCO), a vertically integrated hemp manufacturing company, announced the pricing of an upsized underwritten public offering of 4.2 million shares of its common stock.

HPCO

FibroGen Shares Climb On Strong Q1 Sales

By Erica Kollmann

May 7, 1:10 PM

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46% and is a significant increase over sales of $36.161 million from the same period last year.

FGEN